Minerva Neurosciences, Inc. — Q2 2016 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2016. Minerva is a clinical-stage CNS biopharmaceutical company with four development candidates: MIN-101, MIN-202, MIN-117 and MIN-301. It had no approved products and generated no revenue. Accordingly, operating margins are not meaningful.
Financial performance and position
| Metric | Q2 2016 | Q2 2015 | Six months 2016 | Six months 2015 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development | $2.71m | $4.48m | $8.09m | $8.45m |
| General and administrative | $2.25m | $1.85m | $4.63m | $3.76m |
| Net loss | $5.21m | $6.61m | $13.22m | $12.70m |
| Basic and diluted loss per share | $0.18 | $0.27 | $0.47 | $0.58 |
| Cash used in operations | Not separately reported | Not separately reported | $12.10m | $11.94m |
- At June 30, cash and cash equivalents were $88.67m and marketable securities were $8.39m, totaling approximately $97.06m. Management expected these resources to fund operations into 2018.
- Total assets were $146.50m; current liabilities were $6.24m; total liabilities were $25.90m. Term-loan carrying value was approximately $10.10m, comprising $3.88m current and $6.23m noncurrent. The $10m principal bears fixed interest at 7.05% and matures August 1, 2018.
- Six-month investing cash inflow was $9.44m, from marketable-security maturities. Financing provided $77.05m, principally from the public offering, warrant exercises and a private placement.
- There was no clear company-wide margin measure in the filing; the business had no product revenue and reported operating losses.
Changes versus comparable periods
- Q2 net loss narrowed by about $1.40m year over year, while six-month net loss increased by about $0.51m. Six-month loss per share improved, partly reflecting a higher weighted-average share count.
- Q2 R&D expense fell $1.77m, primarily as MIN-202 spending declined after the funding obligation for the current development phase was met and the MIN-101 and MIN-117 trials reached milestones. Six-month R&D declined $0.36m, with lower MIN-202 expense partly offset by MIN-101, MIN-117 and personnel costs.
- G&A increased $0.40m for the quarter and $0.87m for the half year, mainly due to personnel costs and professional fees.
- Cash and cash equivalents rose from $14.28m at year-end 2015 to $88.67m. The June offering raised $57.5m gross ($53.7m net); warrant exercises generated $22.2m and a director private placement generated approximately $1.0m. Shares outstanding increased from 24.72m at December 31, 2015 to 34.81m at June 30, 2016.
Outlook, clinical developments and risks
- Management expects continued operating losses and negative operating cash flow and says substantial additional funding will be needed for later-stage development, including Phase III trials. Further financing may dilute shareholders or may not be available on acceptable terms; without it, programs could be scaled back or discontinued.
- MIN-101 Phase IIb topline results reported a statistically significant improvement in negative symptoms at both tested doses. The 24-week open-label extension was expected to finish in Q3 2016, followed by discussions with regulators about pivotal-trial design. The company cautioned that its analysis was preliminary and could change; two patients receiving the higher dose were discontinued under QTcF criteria.
- MIN-117 Phase IIa topline results showed dose-dependent effect-size signals versus placebo, but the study was designed for signal detection and was not powered to establish statistical significance between MIN-117 and placebo.
- MIN-202 Phase IIa insomnia results showed positive sleep-parameter signals; Phase Ib MDD results were described as supportive but preliminary. On July 6, 2016, after quarter-end, Minerva and Janssen reached Decision Point 2; Minerva expected to pay up to an additional $19m toward certain Phase II trials. Potential Phase IIb trials in insomnia and MDD were being planned.
- MIN-301 remained in preclinical development; the company anticipated further toxicology and manufacturing work before an IND and/or IMPD filing and a potential Phase I study.
- Key risks include clinical efficacy and safety uncertainty, regulatory delays, reliance on CROs and contract manufacturers, dependence on MTPC and Janssen licenses, intellectual-property protection, and future capital needs. The loans are secured by substantially all assets other than intellectual property and include restrictive covenants. The company disclosed no material pending legal proceeding and stated disclosure controls were effective.
Investor verification priorities
- Review the complete MIN-101 Phase IIb analysis, QTcF findings and extension-study results, and confirm subsequent regulator feedback and pivotal-trial plans.
- Verify Janssen’s development plan, the timing and conditions of the potential additional $19m commitment, and Minerva’s remaining MIN-202 cost exposure.
- Track quarterly cash burn, clinical-trial spending and the assumptions behind management’s runway estimate into 2018, including the effect of planned studies and debt repayments.
- Confirm actual net proceeds and share dilution from 2016 equity and warrant transactions, and assess potential future financing needs.
- Monitor MIN-117’s next-stage evidence and MIN-301’s preclinical, manufacturing and regulatory-pathway milestones.